Bullish Case: Novocure has innovative cancer treatment technologies that have shown promise [beststocks.com], backed by an "outperform" rating from Leerink Partners [beststocks.com].


Show historical bullish cases

Bearish Case: The failure of Novocure's Phase III trial in treating platinum-resistant ovarian cancer has significantly dented investor confidence, sending stock to a five-year low [fool.com][Endpoints][Reuters].


Show historical bearish cases

Takeaway: Novocure's future performance remains uncertain due to its recent trial failure, a potential lawsuit, and market sentiment [fool.com][Endpoints][Reuters][PR News Wire].


Show historical takeaways

Potential Outcomes:

1. 40% chance: If Novocure can successfully recover from the failure of its Phase III trial and demonstrate the effectiveness of its other treatments, the stock price could rebound [beststocks.com].

2. 30% chance: Continued setbacks may further erode investor confidence and the stock price may continue to fall [fool.com][Endpoints][Reuters].

3. 15% chance: The possibility of a lawsuit [PR News Wire] could introduce further volatility and potential decline in the stock price.

4. 15% chance: The company's undervalued stock might attract institutional investors, boosting the stock price [Helium][Helium]. These outcomes were estimated based on the company's current performance, recent set backs, and the potential of legal complications. The estimated probabilities are based on industry trends, recent company news and historical stock performance.


September 12, 2023


NovoCure Forecast

[NVCR]  NovoCure
Price Forecast: BEARISH    Price Action: MEAN REVERTING



Access NVCR Forecasts + Optimized Trading Strategies.







NVCR Balanced News:




Access longer forecasts + daily optimized trades.


Correlated Stock Forecasts

Assets that tend to move strongly with NVCR



BRCC Forecast + Options Trading Strategies   [BRCC]  BRC (0.79)


ZLAB Forecast + Options Trading Strategies   [ZLAB]  Zai Lab (0.77)


AMSWA Forecast + Options Trading Strategies   [AMSWA]  American Software Inc. - (0.76)


ORA Forecast + Options Trading Strategies   [ORA]  Ormat (0.74)


BCRX Forecast + Options Trading Strategies   [BCRX]  Biocryst Pharmaceuticals (0.73)



Uncorrelated Stock Forecasts

Assets with little price relationship to NVCR



IJS Forecast + Options Trading Strategies   [IJS]  BlackRock Institutional Trust Company N.A. - iShares S&P Small-Cap 600 Value (0.0)


AFYA Forecast + Options Trading Strategies   [AFYA]  Afya (0.0)


TECH Forecast + Options Trading Strategies   [TECH]  Bio-Techne (-0.0)


AAXJ Forecast + Options Trading Strategies   [AAXJ]  BlackRock Institutional Trust Company N.A. - iShares MSCI All Country Asia ex Japan (0.01)


HLIT Forecast + Options Trading Strategies   [HLIT]  Harmonic (0.01)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against NVCR



PGTI Forecast + Options Trading Strategies   [PGTI]  PGT Innovations (-0.69)


ERO Forecast + Options Trading Strategies   [ERO]  Ero Copper (-0.69)


ANDE Forecast + Options Trading Strategies   [ANDE]  Andersons (-0.71)


RS Forecast + Options Trading Strategies   [RS]  Reliance Steel & Aluminum (-0.72)


BWXT Forecast + Options Trading Strategies   [BWXT]  BWX (-0.73)